Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Koji Haratani"'
Autor:
Ryohei Yoshida, Maria Saigi, Tetsuo Tani, Benjamin F. Springer, Hirofumi Shibata, Shunsuke Kitajima, Navin R. Mahadevan, Marco Campisi, William Kim, Yoshihisa Kobayashi, Tran C. Thai, Koji Haratani, Yurie Yamamoto, Shriram K. Sundararaman, Erik H. Knelson, Amir Vajdi, Israel Canadas, Ravindra Uppaluri, Cloud P. Paweletz, Juan J. Miret, Patrick H. Lizotte, Prafulla C. Gokhale, Pasi A. Jänne, David A. Barbie
Publikováno v:
Cancer Res
Immunotherapy has shown limited efficacy in patients with EGFR-mutated lung cancer. Efforts to enhance the immunogenicity of EGFR-mutated lung cancer have been unsuccessful to date. Here, we discover that MET amplification, the most common mechanism
Autor:
Kimio Yonesaka, Junko Tanizaki, Osamu Maenishi, Koji Haratani, Hisato Kawakami, Kaoru Tanaka, Hidetoshi Hayashi, Kazuko Sakai, Yasutaka Chiba, Asuka Tsuya, Hiroki Goto, Eri Otsuka, Hiroaki Okida, Maki Kobayashi, Ryoto Yoshimoto, Masanori Funabashi, Yuuri Hashimoto, Kenji Hirotani, Takashi Kagari, Kazuto Nishio, Kazuhiko Nakagawa
Publikováno v:
Clinical Cancer Research. 28:390-403
Purpose: EGFR-tyrosine kinase inhibitor (TKI) is a standard first-line therapy for activated EGFR-mutated non–small cell lung cancer (NSCLC). Treatment options for patients with acquired EGFR-TKI resistance are limited. HER3 mediates EGFR-TKI resis
Autor:
Kimio Yonesaka, Kazuhiko Nakagawa, Koji Haratani, Yoshikane Nonagase, Masayuki Takeda, Tomoaki Hoshino, Hidenobu Ishii, Koichi Azuma, Kaoru Tanaka, Hidetoshi Hayashi
Publikováno v:
Thoracic Cancer, Vol 10, Iss 10, Pp 1928-1935 (2019)
Thoracic Cancer
Thoracic Cancer
Background Non-small cell lung cancer (NSCLC) positive for activating mutations of the epidermal growth factor receptor (EGFR) gene is initially sensitive to EGFR-tyrosine kinase inhibitors (TKIs) but eventually develops resistance to these drugs. Up
Autor:
Koji Haratani, Yoshikane Nonagase, Hisato Kawakami, Kazuhiko Nakagawa, Ryoji Kato, Naoki Takegawa, Hidetoshi Hayashi, Osamu Maenishi, Junji Tsurutani, Masayuki Takeda, Kimio Yonesaka
Publikováno v:
International Journal of Cancer. 145:3414-3424
Therapies targeted to human epidermal growth factor receptor 2 (HER2) have proven effective against tumors positive for HER2 amplification, but there is an unmet clinical need for the treatment of tumors that express HER2 protein in the absence of HE
Autor:
Naoki Takegawa, Hidetoshi Hayashi, Hisato Kawakami, Junji Tsurutani, Junko Tanizaki, Kazuhiko Nakagawa, Kimio Yonesaka, Satomi Watanabe, Masayuki Takeda, Koji Haratani, Yoshikane Nonagase
Publikováno v:
Cancer Medicine
HER2‐targeted therapy, especially the anti‐HER2 antibody trastuzumab, is standard for HER2‐positive breast cancer; however, its efficacy is limited in a subpopulation of patients. HER3 ligand (heregulin)‐dependent HER2‐HER3 interactions pla
Autor:
Ryoji Kato, Naoyuki Maeda, Kaoru Tanaka, Masaaki Miyazawa, Kimio Yonesaka, Hidetoshi Hayashi, Kenji Hirotani, Hisato Kawakami, Masayuki Takeda, Koji Haratani, Kazuhiko Nakagawa, Kazuto Nishio, Junji Tsurutani, Naoki Takegawa, Takashi Kagari, Shiki Takamura, Katsumi Doi, Osamu Maenishi
Immunotherapy targeting programmed cell death-1 (PD-1) induces durable antitumor efficacy in many types of cancer. However, such clinical benefit is limited because of the insufficient reinvigoration of antitumor immunity with the drug alone; therefo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::add21f5a293464472f528b22f0a74f93
https://europepmc.org/articles/PMC6934205/
https://europepmc.org/articles/PMC6934205/
Autor:
Kenji Hirotani, Kazuko Sakai, Satomi Watanabe, Hisato Kawakami, Takashi Kagari, Naoyuki Maeda, Kazuhiko Nakagawa, Koji Haratani, Naoki Takegawa, Kimio Yonesaka, Yasutaka Chiba, Kazuto Nishio
Publikováno v:
Oncogene. 38(9)
EGFR tyrosine kinase inhibitors (TKIs) are standard therapy for EGFR-mutant non-small cell lung cancer (NSCLC); however, these tumours eventually acquire chemoresistance. U3-1402 is an anti-HER3 antibody-drug conjugate with a novel topoisomerase I in
Autor:
Masayuki Takeda, Junko Tanizaki, Hidetoshi Hayashi, Naoki Takegawa, Koji Haratani, Yoshikane Nonagase, Takeshi Yoshida, Satomi Watanabe, Takayuki Takahama, Kimio Yonesaka, Hiroto Ueda, Takao Tamura, Junji Tsurutani, Hisato Kawakami, Kazuhiko Nakagawa, Yasutaka Chiba
Publikováno v:
Oncotarget
// Yoshikane Nonagase 1 , Kimio Yonesaka 1 , Hisato Kawakami 1 , Satomi Watanabe 1 , Koji Haratani 1 , Takayuki Takahama 1 , Naoki Takegawa 1 , Hiroto Ueda 1 , Junko Tanizaki 1 , Hidetoshi Hayashi 1 , Takeshi Yoshida 1 , Masayuki Takeda 1 , Yasutaka